ECP-013: Phenotypic and Genetic Properties in Males at Risk for X-linked Hypohidrotic Ectodermal Dysplasia: Evaluation of an Early Diagnosis Technology and Tests to Assess Nutritional Status

Sponsor
Edimer Pharmaceuticals (Industry)
Overall Status
Completed
CT.gov ID
NCT01629940
Collaborator
(none)
36
1
4
9

Study Details

Study Description

Brief Summary

The investigators propose to obtain facial photographs for use in testing a computer algorithm that recognizes males at high risk for Hypohidrotic Ectodermal Dysplasia (XLHED). FDNA (www.fdna.com), a software company with expertise in the area of facial recognition, is collaborating with the Sponsor in algorithm development based on 2D photographs not requiring special photographic technologies. A frontal facial photograph will be taken at the time of study conduct. The anonymized photographs will be transmitted to FDNA for analysis. A limited number of unaffected controls will be also be recruited.

A subset of affected males between ages 5 and 25 years will have the option of having a blood draw for a set of laboratory studies assessing nutritional status.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    As the first exploratory objective for this study, we propose to obtain facial photographs for use in testing a computer algorithm that recognizes males at high risk for XLHED. While 3D facial profiling has been reported in HED, the technology does not meet the ease-of-use criteria for a universal screening tool. FDNA (www.fdna.com), a software company with expertise in the area of facial recognition, is collaborating with the Sponsor in algorithm development based on 2D photographs not requiring special photographic technologies. All males at risk for a diagnosis of XLHED and attending the 2012 NFED Family Conference will be eligible to participate. A short medical questionnaire will verify the clinical presentation, they will be requested to provide a baby photograph taken at up to 1 month of age (to be returned at study completion), and a frontal facial photograph will be taken at the time of study conduct. The anonymized photographs will be transmitted to FDNA for analysis. A limited number of unaffected controls will be recruited at the 2012 NFED Family Conference for the photography study, in addition to the control data already available in the FDNA database.

    As a second exploratory objective, a subset of affected males between ages 5 and 25 years will have the option of having a blood draw for a set of laboratory studies assessing nutritional status. HED-affected patients in general (including XLHED) are reported to have evidence of growth restriction (weight for height) in this age range without clear mechanistic evidence. A screening panel of nutritional laboratory tests has been designed in collaboration with experts in the field at the University of California, San Francisco (UCSF). Anonymized samples will be analyzed at UCSF.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    36 participants
    Official Title:
    Phenotypic and Genetic Properties in Males at Risk for X-linked Hypohidrotic Ectodermal Dysplasia: Evaluation of an Early Diagnosis Technology and Tests to Assess Nutritional Status
    Study Start Date :
    Jun 1, 2012
    Actual Primary Completion Date :
    Jul 1, 2012
    Actual Study Completion Date :
    Oct 1, 2012

    Arms and Interventions

    Arm Intervention/Treatment
    Male HED-Affected Individuals

    Male subjects affected by HED

    Male controls

    Male subjects not affected by HED

    Outcome Measures

    Primary Outcome Measures

    1. Exploratory Objective - To collect demographic and clinical status information in male subjects affected by HED using a medical questionnaire [Study day 1 - Day of study conduct]

    2. Exploratory Objective - To test and refine a computer algorithm for facial recognition of XLHED based on 2D facial photographs [Study day 1 - Day of study conduct]

    3. Exploratory Objective - To identify nutritional patterns associated with XLHED [Study day 1 - Day of study conduct]

    4. Exploratory Objective - To test for the presence of genetic mutations in a subset of HED-affected subjects enrolled in this study who lack prior genetic diagnosis [Study day 1 - Day of study conduct]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    1. Males of any age who are registered and attending the 2012 NFED Family Conference;

    2. Conform to one of the following requirements for providing informed consent/assent:

    • if more than 18 years of age, subjects must provide signed informed consent;

    • if less than 18 years of age and it is determined that the subject is capable of providing assent, both the assent of the subject and consent of the parent(s) or guardian of that subject must be granted. Under this condition, both parents of the subject should give their permission, unless 1 parent is deceased, unknown, incompetent, or not available;

    • if the subject is incapable of providing assent, the consent of the parent(s) or guardian of the subject must be granted. Under this condition, both parents should give their consent, unless 1 parent is deceased, unknown, incompetent, or not available.

    1. As described in Section 3.2 above, subjects must meet one of the following criteria:
    • Male subjects of original gender with genetic confirmation of an EDA mutation or with the clinical characteristics of HED including a history of decreased sweating;

    • Unaffected, healthy male controls.

    Exclusion Criteria:
    1. Subjects who are not able or are not willing to comply with the procedures of this protocol.

    2. Subjects with any major medical problem that will prevent them from participating in this study.

    3. HED-affected male subjects who have had prior genetic testing confirming they do not have the X-linked form of the disorder.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Buenavista Palace Hotel and Spa Orlando Florida United States 22206

    Sponsors and Collaborators

    • Edimer Pharmaceuticals

    Investigators

    • Principal Investigator: Dorothy K Grange, MD, Washington University School of Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Edimer Pharmaceuticals
    ClinicalTrials.gov Identifier:
    NCT01629940
    Other Study ID Numbers:
    • ECP-013
    First Posted:
    Jun 28, 2012
    Last Update Posted:
    Dec 18, 2012
    Last Verified:
    Dec 1, 2012

    Study Results

    No Results Posted as of Dec 18, 2012